Translating Multimodal Biomarker Strategies from Preclinical Models to Early Clinical Development in ALS
11:30 am - Wednesday 2nd December 2026
- Building a multimodal biomarker strategy across early development: integrating blood-based transcriptomics, CSF markers, pharmacodynamic readouts, and disease-relevant endpoints in a Phase I ALS programme
- Leveraging public datasets to de-risk biomarker selection by mining gene expression and proteomic data to identify translatable signatures, aligning preclinical model readouts with human datasets, and validating candidates through access to patient-derived samples
- Designing biomarkers for small, early-phase cohorts through selecting and prioritising analytes, developing bespoke assays, and ensuring translational relevance ahead of patient readouts
NEW DATA
